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Purpose of the study
In 1996 Santos was the first city in Brazil to include HIV-
1 antiretroviral therapy. After advent of HAART, morbid-
ity and mortality rates decreased in this location. How-
ever, due to sequential therapy, antiretroviral failure and
resistance are assumed to be high. Our objective has been
to assess the immunological benefit to individuals under
HAART with and without virologic suppression.
Methods
We studied 2,854 patients treated with antiretroviral ther-
apy. Patients with 3 years continuous suppression of
viremia (<50 HIV-RNA copies/ml, b-DNA, Siemens) were
classified as group 1 and patients with 3 years continuous
viremia (viral load >10,000 HIV-RNA copies/ml) were
classified as group 2. The CD4+ and CD8+ T-cell data were
retrospectively analyzed for the years 2005, 2006 and
2007.
Summary of results
267 (9.4%) patients on follow-up belonged to group 1
and 48 (1.7%) patients were classified as group 2. The
average CD4+ T-cell counts for group 1 was 642, 660, 722
cells/mm3 in 2005, 2006 and 2007, respectively, and
CD8+T average was 1085, 987, 1006. The group 2 average
CD4+T count was 427, 368, 315, and CD8+T mean: 1310,
1247, 1193 cells/mm3. There was a continuous increase
in the CD4+ T-cell counts over time in group 1 (ANOVA,
p < 0.05,), as well as a decline in group 2 (p < 0.01).
Conclusion
Although there have been descriptions of a continuous
immunologic benefit among individuals under antiretro-
viral treatment in spite of virologic failure, it is clear that
moderate to high levels of viremia will lead to a decrease
in the average CD4 counts in a relatively short period of
time in this population. Interestingly, both groups
showed an equally high level of CD8+T cells in spite of the
degree of viral suppression. Only 9.4% under treatment in
the public system in this key location in Brazil present
long-term viral suppression, which may be the character-
istic of developing countries with widespread access to all
FDA licensed antiretrovirals for all patients free of cost.
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